Granisetron
- Generic Name
- Granisetron
- Brand Names
- Sancuso, Sustol
- Drug Type
- Small Molecule
- Chemical Formula
- C18H24N4O
- CAS Number
- 109889-09-0
- Unique Ingredient Identifier
- WZG3J2MCOL
- Background
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
- Indication
For the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).
- Associated Conditions
- Nausea and vomiting
- Associated Therapies
- -
An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2008-04-25
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 208
- Registration Number
- NCT00666783
- Locations
- 🇨🇳
Xijng Hospital, Xi,an, Shaanxi, China
A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fasting Conditions
- First Posted Date
- 2008-02-19
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 32
- Registration Number
- NCT00618254
- Locations
- 🇺🇸
MDS Pharma Services, Lincoln, Nebraska, United States
A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fed Conditions
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 32
- Registration Number
- NCT00618111
- Locations
- 🇺🇸
MDS Pharma Services, Lincoln, Nebraska, United States
The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects
- Conditions
- Interventions
- First Posted Date
- 2007-08-06
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT00511823
- Locations
- 🇺🇸
GSK Investigational Site, Evansville, Indiana, United States
Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting
- Conditions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Target Recruit Count
- 144
- Registration Number
- NCT00503386
- Locations
- 🇨🇳
Fujian Provincial Tumor Hospital, Fuzhou, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Jiangsu Provincial Tumor Hospital, Nanjing, Jiangsu, China
The Antigagging Effect of Granisetron (Kytril), an Antiemetic Drug, in Dental Situations
- Conditions
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2010-11-30
- Lead Sponsor
- Hadassah Medical Organization
- Registration Number
- NCT00502437
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2015-01-27
- Target Recruit Count
- 31
- Registration Number
- NCT00450853
- Locations
- 🇪🇸
Clinica Universitaria de Navarra, Pamplona, Navarra, Spain
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 22
- Registration Number
- NCT00450801
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
- Conditions
- Interventions
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 196
- Registration Number
- NCT00415103
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Spain
🇪🇸Hospital Universitario Marqués de Valdecilla, Santander, Spain
🇪🇸Hospital Universitario la Princesa, Madrid, Spain
To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)
- Conditions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 630
- Registration Number
- NCT00273468
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.